“nominally significant”

We extracted nominally significant genes (at P < 0.1, P < 0.05, and P < 0.01) from Vegas2 outputs for each of the two traits and assessed those for overlapping genes between endometriosis and migraine.

Neutropenia, fatigue, anaemia, combined haematological toxicity and constipation were nominally significant ( P <0.1) for either BCSS or RFS (or both) on univariable analysis (Table 2 ).

Additionally, in cases where either missense-variant score test used in the sLRT was nominally significant ( p < 0.1), we combined missense and protein LOF variants for joint tests.

Given the lower number of FDR-significant hits, we used a nominally significant threshold (FDR-corrected p value < 0.10) to assess pathways.

For example 35 of 49 cells with cell cycle defects in one or more embryos also had a nominally significant difference in mean cell cycles (p < 0.1; FDR < 0.15; S2 Table ).

Noting these limitations, these analyses found nominally significant ( p < 0.10) interaction effects for FeNO in both tralokinumab treatment groups and for periostin in the Q4W, but not the Q2W, group (Table 2 ).

In the two cases where the random effect term was nominally significant ( P < 0.1), a linear mixed-effect model was fit using the lme package in R to obtain an estimate and 95% confidence interval for the same ratio.

Nominally significant trends (p ≤ 0.10) in reducing plasma levels of Aβ40, Aβ42, and NfL were also observed in zervimesine vs. placebo treated participants, which provides support for a role of zervimesine in impacting amyloid biology, neuroinflammation and neurodegeneration in patients with mild to moderate AD that have lower than 1 pg/ml p-tau17 levels at baseline using the AlzPath Dx assay.

Gene-sets with nominally significant burden for at least one variant category ( P < 0.10 for LoF and splicing regulatory, and P < 0.05 for missense variants) were then tested for the joint burden of the three variant categories with a multivariate, two-sample Hotelling’s T-Square test ( Hotelling 1931 ).

Six of these directionally consistent SNPs also had a p-value <0.1 in AA, which we consider nominally significant for a one-sided test suggesting modest enrichment for EA CAC alleles within our AA sample (EA CAC GWAS significant SNPs with replication p values <0.10 in AA CAC meta-analysis shown in Table 2 , results for all previously reported suggestive SNPs (p < 1E-05) in EA CAC have AA CAC results reported in Additional file 1 : Table S3).

Following 24 hours of cyclical longitudinal strain (10%, 1 Hz), RNA sequencing identified 1761 transcripts that were nominally significant (adjusted P <0.1), of which 232 transcripts were statistically significant after correction for multiple testing (adjusted P <1.6×10 −6 ; Figure 8A, 8B and Figure S5 ).

Permutation-based enrichment analysis For those results that showed nominally significant ( P < 0.10) evidence for enrichment in χ 2 tests of contingency tables, we performed permutation-based analyses to obtain empirical estimates of significance of enrichment.

As the composite association of all genotyped SNPs proved to be quite small, GRS analysis was also conducted using the subset of SNPs that were or approaching a nominally significant value ( p < 0.1), which comprised of rs2506142, rs11624776, rs6724624, rs1925950, rs6693567, rs6791480 and rs111172113.

Nominally significant ( P < 0.10) SNP from the initial model are reported (Table 4 ).

3.3 Secondary outcomes Analyses for secondary outcomes were pre‐specified; however, given the fact that the trial was not powered to detect a difference in these outcomes and no corrections were made for multiple comparisons, all effects with p < 0.05 are considered nominally significant, and effects p < 0.10 but ≥ 0.05 are considered trends.

Post-hoc P-values < 0.05 reported as nominally significant and P-values < 0.1 reported, for exploratory purposes.

p ‐Values <0.05 were regarded as being nominally significant with GROUP p ‐values <0.1 on the memory measures after Benjamini–Hochberg adjustment regarded as surviving correction for multiple comparisons.

Twelve nominally significant genes that had P -values <0.1 were tested for pairwise G × G interactions, as in Ref. 12 .

We considered batch-corrected serum metabolite response (RPA) differences nominally significant at P < 0.10 (without correction for multiple testing) candidates for multivariate analyses ( 43 ).

Out of these, diagnosis, graft type, donor age, and principal component 5 each had a nominally significant association ( p -value < 0.1) with relapse status (Supplementary Table 1 ).

Out of the 275 Lyme-comorbidity combinations (restricting to those with at least 20 affected patients of both conditions) for all time windows, 21 were nominally significant, with 5 diseases occurring prior to LD and 16 occurring after ( p < 0.1 due to the relatively small sample size; Table 1 ).

Those variables that were nominally significant at the P < 0.15 level, with respect to overall FSD, with no adjustment for multiple comparisons, were used in a multivariate logistic regression model.

The adjusted estimate for ever-smoking was attenuated and no longer nominally significant (adjusted HR 1·6, 95% CI 0·8–3·0, p = 0·16), and the same pattern was observed for diabetes mellitus (1·9, 1·0–3·6, p = 0·061).

On stratifying by weight status, the association of PC2-Z with serum TG and GGT was nominally significant, and remained close to significance after FDR correction in all groups ( P < 0.17), except for underweight children (Supplemental Table 6 ).

Although there were nominal ASD-associated increases in astrocyte (AST1) and decreases in lower-layer excitatory neuronal (EX7 and EX8) proportions, the changes were of small magnitude and reflect a nominally significant trend (FDR-corrected P- values > 0.18; Extended Data Fig. 9 and Supplementary Data 8 ).